Treatment for Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Alcoholic Fatty Liver Disease (NAFLD)+1 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is assessing the prevalence of two liver diseases, Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), and assembling a cohort of adults with these diseases to better understand them.

Eligible Conditions
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Miricorilant Dose Escalation
1
OA-235i (4-30 mg)
1
Intervention/ Drug

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Long-term health outcomes
Prevalence of NAFLD and NASH in the population

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Miricorilant Dose Escalation
1
OA-235i (4-30 mg)
1
Intervention/ Drug

Trial Design

0 Treatment Group

800 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,918 Previous Clinical Trials
3,506,180 Total Patients Enrolled
ALINA M ALLEN, MDPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a resident of Olmsted County at the time of search.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top